171 related articles for article (PubMed ID: 33955165)
1. Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.
Qu Y; Gao B; Arimura Z; Fang M; Vargas HM
Clin Transl Sci; 2021 Jul; 14(4):1600-1610. PubMed ID: 33955165
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of physiological late Na
El-Bizri N; Li CH; Liu GX; Rajamani S; Belardinelli L
Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H236-H245. PubMed ID: 28971840
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
Ligneau X; Shah RR; Berrebi-Bertrand I; Mirams GR; Robert P; Landais L; Maison-Blanche P; Faivre JF; Lecomte JM; Schwartz JC
Br J Pharmacol; 2017 Dec; 174(23):4449-4463. PubMed ID: 28941245
[TBL] [Abstract][Full Text] [Related]
4. Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.
Gao B; Sutherland W; Vargas HM; Qu Y
Pharmacol Res Perspect; 2020 Oct; 8(5):e00656. PubMed ID: 32969560
[TBL] [Abstract][Full Text] [Related]
5. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
6. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.
Fülöp GÁ; Oláh A; Csipo T; Kovács Á; Pórszász R; Veress R; Horváth B; Nagy L; Bódi B; Fagyas M; Helgadottir SL; Bánhegyi V; Juhász B; Bombicz M; Priksz D; Nanasi P; Merkely B; Édes I; Csanádi Z; Papp Z; Radovits T; Tóth A
Basic Res Cardiol; 2021 Apr; 116(1):24. PubMed ID: 33844095
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes.
Szentandrassy N; Horvath B; Vaczi K; Kistamas K; Masuda L; Magyar J; Banyasz T; Papp Z; Nanasi PP
J Physiol Pharmacol; 2016 Aug; 67(4):483-489. PubMed ID: 27779469
[TBL] [Abstract][Full Text] [Related]
8. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
[TBL] [Abstract][Full Text] [Related]
9. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
[TBL] [Abstract][Full Text] [Related]
11. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
[TBL] [Abstract][Full Text] [Related]
13. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
Dashwood A; Cheesman E; Wong YW; Haqqani H; Beard N; Hay K; Spratt M; Chan W; Molenaar P
Pharmacol Res Perspect; 2021 May; 9(3):e00760. PubMed ID: 33929079
[TBL] [Abstract][Full Text] [Related]
14. Human ex-vivo action potential model for pro-arrhythmia risk assessment.
Page G; Ratchada P; Miron Y; Steiner G; Ghetti A; Miller PE; Reynolds JA; Wang K; Greiter-Wilke A; Polonchuk L; Traebert M; Gintant GA; Abi-Gerges N
J Pharmacol Toxicol Methods; 2016; 81():183-95. PubMed ID: 27235787
[TBL] [Abstract][Full Text] [Related]
15. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
16. Cardiac electrophysiological effects of ibuprofen in dog and rabbit ventricular preparations: possible implication to enhanced proarrhythmic risk.
Pászti B; Prorok J; Magyar T; Árpádffy-Lovas T; Györe B; Topál L; Gazdag P; Szlovák J; Naveed M; Jost N; Nagy N; Varró A; Virág L; Koncz I
Can J Physiol Pharmacol; 2021 Jan; 99(1):102-109. PubMed ID: 32937079
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol inhibits multiple cardiac ion channels and shortens ventricular action potential duration in vitro.
Le Marois M; Ballet V; Sanson C; Maizières MA; Carriot T; Chantoiseau C; Partiseti M; Bohme GA
Eur J Pharmacol; 2020 Nov; 886():173542. PubMed ID: 32910945
[TBL] [Abstract][Full Text] [Related]
18. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
19. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
20. Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium.
Shchepkin DV; Nabiev SR; Nikitina LV; Kochurova AM; Berg VY; Bershitsky SY; Kopylova GV
Biochem Biophys Res Commun; 2020 Aug; 528(4):658-663. PubMed ID: 32513536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
